A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations
Authors' conclusion
The results of the meta-analysis showed no significant association between SGLT-2i use and PAD and amputation risks in diabetic patients when used for shorter treatment durations.
Study context
- Population
- Patients with diabetes in randomized controlled trials (RCTs) (Medline and Central databases)
- Participants
- 97,589 patients51 RCTs
- Comparison
- SGLT2i vs placebo/active comparators
- Outcome
- Amputation events and PAD
Methodological detailsrandom-effects model, subgroup analyses
- Random-effects model
- Subgroup analyses
Pooled result
As reported in the abstract
- Significant increase in peripheral artery disease (PAD) risk with SGLT-2i vs placebo/active comparators
- No significant increase in amputation risk with SGLT-2i vs placebo/active comparators
- SGLT-2i vs Placebo/active comparators: P = 0.04
- SGLT-2i vs Placebo/active comparators: P = 0.43
- Random-effects model
Further pooled results
Subgroups: SGLT-2i type, treatment duration, patient risk factors
- No significant difference between SGLT-2i type, duration of treatment or patient risk factors on amputation or PAD incidence
Subgroup: treatment length >100 weeks · > 100 weeks
- Treatment >100 weeks associated with significant increase in both PAD and amputation risks with SGLT-2i
Original publication
A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations. Diabetes Obes Metab. Published 12 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →